The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice

Diabetologia

Volumn 55, Issue 10, 2012, Pages 2779-2788

  Vollert, S ^a   Kaessner, N ^b   Heuser, A ^a   Hanauer, G ^b   Dieckmann, A ^b   Knaack, D ^c   Kley, H P ^b   Beume, R ^b   Weiss Haljiti, C ^b  

^a Nycomed GmbH   (Germany)

^b Nycomed   (Germany)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Beta cells; GLP 1; HbA1c; Insulin; Intestine; Islets; Modelling; Obesity; Pharmacokinetic; PKPD

Indexed keywords

DRUG METABOLITE; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; ROFLUMILAST N OXIDE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FLUID INTAKE; FOOD INTAKE; GLUCAGON LIKE PEPTIDE 1 BLOOD LEVEL; GLUCOSE BLOOD LEVEL; IC 50; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SINGLE DRUG DOSE; TREATMENT DURATION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; BENZAMIDES; BLOOD GLUCOSE; CYCLOPROPANES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, MUTANT STRAINS; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84866137028     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2632-z     Document Type: Article

References (30)

1. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398 (Pubitemid 43132818)
2. Hatzelmann A, Morcillo EJ (2010) The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235-256
3. Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127-162 (Pubitemid 30394536)
4. Zhang R, Maratos-Flier E, Flier JS (2009) Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150:3076-3082
5. Park SJ, Ahmad F, Philp A et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421-433
6. Waddleton D, Wu W, Feng Y et al (2008) Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochem Pharmacol 76:884-893
7. Ong WK, Gribble FM, Reimann F et al (2009) The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 157:633-644
8. Omar B, Zmuda-Trzebiatowska E, Manganiello V, Göransson O, Degerman E (2009) Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal 21:760-766
9. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165
10. Hummel KP, Dickie MM, Coleman DL (1966) Diabetes, a new mutation in the mouse. Science 153:1127-1128
11. Yamazaki M, Kato A, Kato C et al (2009) Segmentation of the pathophysiological stages of diabetic changes in the db/db mouse. J Toxicol Pathol 22:133-137
12. Lahu G, Hünnemeyer A, Herzog R et al (2009) Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 47:236-245
13. Rütti S, Ehses JA, Sibler RA et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521-4530
14. Bethke TD, Böhmer GM, Hermann R et al (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47:26-36 (Pubitemid 44973995)
15. Gribble FM (2008) RD Lawrence Lecture 2008: targeting GLP-1release as a potential strategy for the therapy of type 2 diabetes. Diabet Med 25:889-894
16. Lund A, Knop FK, Vilsboll T (2011) Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs 16:607-618
17. Rabe K (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163(1):53-67
18. Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT (2004) Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized double-blind trial. Am J Med 116:223-229 (Pubitemid 38224229)
19. Inzuchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372
20. UK Prospective Diabetes Study Group (1998) UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175
21. Fehmann HC, Habener JF (1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130:159-166
22. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266 (Pubitemid 24143111)
23. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg CJ, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806-815 (Pubitemid 38756992)
24. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-1452 (Pubitemid 34826610)
25. Stoffers DA, Kieffer TJ, Hussain MA et al (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748 (Pubitemid 30339989)
26. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276 (Pubitemid 30395416)
27. Zhou J, Wang X, Pineyro MA, Egan JM (1999) Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366 (Pubitemid 30395427)
28. Rolin B, Larsen MO, Gotfredsen CF et al (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745-E752
29. Cernea S, Raz I (2011) Therapy in the early stage: incretins. Diabetes Care 34:S264-S271
30. Lahu G, Hünnemeyer A, Diletti E et al (2010) Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49:589-606